诺思格收盘上涨3.15%，滚动市盈率36.51倍，总市值51.19亿元

Group 1 - The core viewpoint of the articles highlights the performance and market position of Norsg in the medical services industry, noting its stock price increase and financial metrics [1][2] - As of April 1, Norsg's closing stock price was 53.0 yuan, reflecting a 3.15% increase, with a rolling PE ratio of 36.51 times and a total market capitalization of 5.119 billion yuan [1] - The average PE ratio for the medical services industry is 52.86 times, with a median of 49.90 times, placing Norsg at the 26th position within the industry [1][2] Group 2 - Norsg's main business involves providing comprehensive drug clinical development services to global pharmaceutical companies and research institutions, including clinical trial operation services and data management [1] - For the fiscal year 2024, Norsg reported a revenue of 744 million yuan, representing a year-on-year increase of 3.14%, while net profit was 140 million yuan, showing a year-on-year decrease of 13.73% [1] - The company's gross profit margin stands at 37.09% [1]